Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25635538 | 0.85 | KDM1A (0.43) | CHRNA1CHRNB1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL14336880 | 0.81 | SLC6A3 (0.37) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL14336875 | 0.77 | POLB (0.34) | SLC6A2SLC6A3 | |
| SCHEMBL25635636 | 0.75 | HCRTR2 (0.31) | — | |
| SCHEMBL25635554 | 0.71 | PGR (0.35) | SLC6A2SLC6A3 | |
| SCHEMBL15420336 | 0.69 | HDAC3 (0.38) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL25635545 | 0.69 | — | — | |
| SCHEMBL21427332 | 0.68 | LPL (0.39) | — | |
| SCHEMBL25635548 | 0.66 | CYP3A4 (0.32) | — | |
| SCHEMBL25635576 | 0.65 | CDK5 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4118092-B1 | IMMUNOMODULATING O-HET-ARYL AZALIDES | ZOETIS SERVICES LLC (US) | 2025-07-16 | — | — | EP | claimed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025087291-A1 | IRAK4 TARGETED DEGRADATION AGENT COMPOUND, AND USE THEREOF | 江苏先声药业有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025077891-A1 | DEGRADATION AGENT COMPOUND TARGETING IRAK4, AND USE THEREOF | 江苏先声药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20240368214-A1 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4392432-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4200295-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2023028278-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | CHRNA1 198/4885CHRNG 464/4885CHRNB1 367/4885 |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | CHRNA1 291/4885CHRNG 518/4885CHRNB1 502/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | CHRNA1 291/4885CHRNG 518/4885CHRNB1 502/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | CHRNA1 3134/4885CHRNG 3113/4885CHRNB1 2603/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | CHRNA1 342/4885CHRNG 576/4885CHRNB1 657/4885 |
| US-20240368214-A1 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | GRIN1, GRIN3A, GRIN2B | CHRNA1 199/4885CHRNG 189/4885CHRNB1 272/4885 |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | CHRNA1 342/4885CHRNG 576/4885CHRNB1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.